These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 10467820)

  • 1. Compounding botanicals: a legal perspective.
    Valentino JG; Bormel FG
    J Am Pharm Assoc (Wash); 1999; 39(4):537-44. PubMed ID: 10467820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Explanations and unresolved issues pertaining to the development of the Nuclear Pharmacy Compounding Guidelines.
    Hung JC; Augustine SC; Cheng KT; Green RL; Hopkins WM; Laven DL; Nelson BR; Petry NA; Ponto JA; Quinton TM; Swanson DP
    J Am Pharm Assoc (Wash); 2002; 42(5):789-98. PubMed ID: 12269713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential risks of pharmacy compounding.
    Gudeman J; Jozwiakowski M; Chollet J; Randell M
    Drugs R D; 2013 Mar; 13(1):1-8. PubMed ID: 23526368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. List of drug products that have been withdrawn or removed from the market for reasons of safety or effectiveness. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 1999 Mar; 64(44):10944-7. PubMed ID: 10557618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of the compounding of positron emission tomography drugs.
    Hung JC
    Am J Health Syst Pharm; 2001 Jan; 58(2):134-9. PubMed ID: 11202536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applying Quality by Design Concepts to Pharmacy Compounding.
    Timko RJ
    Int J Pharm Compd; 2015; 19(6):453-63. PubMed ID: 26891559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. List of drug products that have been withdrawn or removed from the market for reasons of safety or effectiveness--FDA. Proposed rule.
    Fed Regist; 1998 Oct; 63(195):54082-9. PubMed ID: 10185826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on medical and regulatory issues pertaining to compounded and FDA-approved drugs, including hormone therapy.
    Pinkerton JV; Pickar JH
    Menopause; 2016 Feb; 23(2):215-23. PubMed ID: 26418479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of the Food and Drug Administration's current good manufacturing practices regulations to pharmacy practice: a legal view.
    Fink JL
    Contemp Pharm Pract; 1979; 2(4):202-5. PubMed ID: 10244540
    [No Abstract]   [Full Text] [Related]  

  • 10. Final guidance for pharmacy compounding of human drug products under Section 503A.
    Blankenship CE
    Int J Pharm Compd; 2014; 18(5):379-80. PubMed ID: 25577886
    [No Abstract]   [Full Text] [Related]  

  • 11. Compounding pharmacy conundrum: "we cannot live without them but we cannot live with them" according to the present paradigm.
    Guharoy R; Noviasky J; Haydar Z; Fakih MG; Hartman C
    Chest; 2013 Apr; 143(4):896-900. PubMed ID: 23412546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PreScription: Comments on the FDA Guidance "Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry".
    Allen LV
    Int J Pharm Compd; 2022; 26(2):92. PubMed ID: 35413006
    [No Abstract]   [Full Text] [Related]  

  • 13. A pharmacist-driven Food and Drug Administration incident surveillance and response program for compounded drugs.
    Janusziewicz AN; Glueck SN; Park SY; Nguyen DN; Rimmel SC; Cascio LA; Doh GY; Martin-Yeboah GF
    Am J Health Syst Pharm; 2021 Jul; 78(15):1438-1443. PubMed ID: 33889929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of compounding by the food and drug administration: a tale of 2 circuits.
    Williams KG
    J Pharm Pract; 2010 Oct; 23(5):502-6. PubMed ID: 21507854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What gastroenterologists should know about the gray market, herbal remedies, and compounded pharmaceuticals and their regulation by the Food and Drug Administration.
    Ehrenpreis ED; Kulkarni P; Burke C;
    Am J Gastroenterol; 2013 May; 108(5):642-6. PubMed ID: 23644956
    [No Abstract]   [Full Text] [Related]  

  • 16. Compounding for animal patients: contemporary issues.
    Lust E
    J Am Pharm Assoc (2003); 2004; 44(3):375-84; quiz 384-6. PubMed ID: 15191248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dietary supplements: What's in a name? What's in the bottle?
    Marcus DM
    Drug Test Anal; 2016; 8(3-4):410-2. PubMed ID: 27072845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dietary Supplements: Foods, Medicines, or Both? A Controversial Designation with Unspecific Legislation.
    Pereira C; Barros L; Ferreira ICFR
    Curr Pharm Des; 2017; 23(19):2722-2730. PubMed ID: 28124610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron-containing supplements and drugs; label warning statements and unit-dose packaging requirements; removal of regulations for unit-dose packaging requirements for dietary supplements and drugs. Final rule; removal of regulatory provisions in response to court order.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Oct; 68(201):59714-5. PubMed ID: 14567392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An overview of herb and dietary supplement efficacy, safety and government regulations in the United States with suggested improvements. Part 1 of 5 series.
    Brown AC
    Food Chem Toxicol; 2017 Sep; 107(Pt A):449-471. PubMed ID: 27818322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.